18 related articles for article (PubMed ID: 28834279)
1. The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib.
Chen S; Li X; Li Y; He X; Bryant M; Qin X; Li F; Seo JE; Guo X; Mei N; Guo L
Toxicol Sci; 2023 Dec; 197(1):69-78. PubMed ID: 37788138
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Marcath LA; Deal AM; Van Wieren E; Danko W; Walko CM; Ibrahim JG; Weck KE; Jones DR; Desta Z; McLeod HL; Carey LA; Irvin WJ; Hertz DL
Pharmacogenet Genomics; 2017 Nov; 27(11):402-409. PubMed ID: 28877533
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Sanchez Spitman AB; Moes DJAR; Gelderblom H; Dezentje VO; Swen JJ; Guchelaar HJ
Eur J Clin Pharmacol; 2017 Dec; 73(12):1589-1598. PubMed ID: 28849250
[TBL] [Abstract][Full Text] [Related]
4. Design and Characterization of Maltoheptaose-
Villetti MA; Clementino AR; Dotti I; Ebani PR; Quarta E; Buttini F; Sonvico F; Bianchera A; Borsali R
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770918
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
Crewe HK; Notley LM; Wunsch RM; Lennard MS; Gillam EM
Drug Metab Dispos; 2002 Aug; 30(8):869-74. PubMed ID: 12124303
[TBL] [Abstract][Full Text] [Related]
6. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Lu WJ; Xu C; Pei Z; Mayhoub AS; Cushman M; Flockhart DA
Breast Cancer Res Treat; 2012 May; 133(1):99-109. PubMed ID: 21814747
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
9. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
10. The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro.
Ma J; Chu Z; Lu JBL; Liu J; Zhang Q; Liu Z; Tang D
Chem Biodivers; 2018 Jan; 15(1):. PubMed ID: 28834279
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
